161 related articles for article (PubMed ID: 19329185)
1. Transcriptional activation of Skp2 by BCR-ABL in K562 chronic myeloid leukemia cells.
Chen JY; Wang MC; Hung WC
Leuk Res; 2009 Nov; 33(11):1520-4. PubMed ID: 19329185
[TBL] [Abstract][Full Text] [Related]
2. Bcr-Abl-induced tyrosine phosphorylation of Emi1 to stabilize Skp2 protein via inhibition of ubiquitination in chronic myeloid leukemia cells.
Chen JY; Wang MC; Hung WC
J Cell Physiol; 2011 Feb; 226(2):407-13. PubMed ID: 20717963
[TBL] [Abstract][Full Text] [Related]
3. BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells.
Andreu EJ; Lledó E; Poch E; Ivorra C; Albero MP; Martínez-Climent JA; Montiel-Duarte C; Rifón J; Pérez-Calvo J; Arbona C; Prósper F; Pérez-Roger I
Cancer Res; 2005 Apr; 65(8):3264-72. PubMed ID: 15833859
[TBL] [Abstract][Full Text] [Related]
4. [Study on mismatch repair genes of chronic myeloid leukemia].
Luo J; Peng ZG; Chen Y; Lai YR; Lu YY; Song SJ
Zhonghua Xue Ye Xue Za Zhi; 2006 Feb; 27(2):103-6. PubMed ID: 16732964
[TBL] [Abstract][Full Text] [Related]
5. Imatinib (STI571) induces DNA damage in BCR/ABL-expressing leukemic cells but not in normal lymphocytes.
Czechowska A; Poplawski T; Drzewoski J; Blasiak J
Chem Biol Interact; 2005 Apr; 152(2-3):139-50. PubMed ID: 15840387
[TBL] [Abstract][Full Text] [Related]
6. Abnormalities in glucose uptake and metabolism in imatinib-resistant human BCR-ABL-positive cells.
Kominsky DJ; Klawitter J; Brown JL; Boros LG; Melo JV; Eckhardt SG; Serkova NJ
Clin Cancer Res; 2009 May; 15(10):3442-50. PubMed ID: 19401345
[TBL] [Abstract][Full Text] [Related]
7. Imatinib-resistant K562 cells are more sensitive to celecoxib, a selective COX-2 inhibitor: role of COX-2 and MDR-1.
Arunasree KM; Roy KR; Anilkumar K; Aparna A; Reddy GV; Reddanna P
Leuk Res; 2008 Jun; 32(6):855-64. PubMed ID: 18083230
[TBL] [Abstract][Full Text] [Related]
8. ABL1 promoter methylation can exist independently of BCR-ABL transcription in chronic myeloid leukemia hematopoietic progenitors.
Sun B; Jiang G; Zaydan MA; La Russa VF; Safah H; Ehrlich M
Cancer Res; 2001 Sep; 61(18):6931-7. PubMed ID: 11559572
[TBL] [Abstract][Full Text] [Related]
9. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
[TBL] [Abstract][Full Text] [Related]
10. Quantification of bcr/abl mRNA expression by a rapid real-time reverse transcription-polymerase chain reaction assay in patients with chronic myeloid leukemia.
Zanella I; Rossi G; Finazzi D; Capucci A; Albertini A; Cariani E
Haematologica; 2001 Mar; 86(3):318-9. PubMed ID: 11255281
[No Abstract] [Full Text] [Related]
11. Sensitization of imatinib-resistant CML cells to TRAIL-induced apoptosis is mediated through down-regulation of Bcr-Abl as well as c-FLIP.
Park SJ; Kim MJ; Kim HB; Kang CD; Kim SH
Biochem J; 2009 Apr; 420(1):73-81. PubMed ID: 19203346
[TBL] [Abstract][Full Text] [Related]
12. Killing of leukemic cells with a BCR/ABL fusion gene by RNA interference (RNAi).
Wilda M; Fuchs U; Wössmann W; Borkhardt A
Oncogene; 2002 Aug; 21(37):5716-24. PubMed ID: 12173041
[TBL] [Abstract][Full Text] [Related]
13. Molecular response to imatinib in patient with Ph negative p190 BCR-ABL transcript positive chronic myeloid leukemia with cyclic leukocytosis.
Radojkovic M; Ristic S; Pavlovic S; Colovic M
Leuk Res; 2009 Jun; 33(6):e10-2. PubMed ID: 19091403
[TBL] [Abstract][Full Text] [Related]
14. c-Jun blocks cell differentiation but not growth inhibition or apoptosis of chronic myelogenous leukemia cells induced by STI571 and by histone deacetylase inhibitors.
Huang HM; Liu JC
J Cell Physiol; 2009 Mar; 218(3):568-74. PubMed ID: 19006173
[TBL] [Abstract][Full Text] [Related]
15. Bcr-Abl-independent mechanism of resistance to imatinib in K562 cells: Induction of cyclooxygenase-2 (COX-2) by histone deacetylases (HDACs).
Kalle AM; Sachchidanand S; Pallu R
Leuk Res; 2010 Sep; 34(9):1132-8. PubMed ID: 20206383
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
Kurosu T; Ohki M; Wu N; Kagechika H; Miura O
Cancer Res; 2009 May; 69(9):3927-36. PubMed ID: 19366808
[TBL] [Abstract][Full Text] [Related]
17. Effect of imatinib on the signal transduction cascade regulating telomerase activity in K562 (BCR-ABL-positive) cells sensitive and resistant to imatinib.
Mor-Tzuntz R; Uziel O; Shpilberg O; Lahav J; Raanani P; Bakhanashvili M; Rabizadeh E; Zimra Y; Lahav M; Granot G
Exp Hematol; 2010 Jan; 38(1):27-37. PubMed ID: 19837126
[TBL] [Abstract][Full Text] [Related]
18. Cotreatment with apicidin overcomes TRAIL resistance via inhibition of Bcr-Abl signaling pathway in K562 leukemia cells.
Park SJ; Kim MJ; Kim HB; Sohn HY; Bae JH; Kang CD; Kim SH
Exp Cell Res; 2009 Jul; 315(11):1809-18. PubMed ID: 19268463
[TBL] [Abstract][Full Text] [Related]
19. Modulation of caspase-independent cell death leads to resensitization of imatinib mesylate-resistant cells.
Lavallard VJ; Pradelli LA; Paul A; Bénéteau M; Jacquel A; Auberger P; Ricci JE
Cancer Res; 2009 Apr; 69(7):3013-20. PubMed ID: 19318579
[TBL] [Abstract][Full Text] [Related]
20. Specific assessment of BCR-ABL transcript overexpression and imatinib resistance in chronic myeloid leukemia patients.
Bianchini M; De Brasi C; Gargallo P; Gonzalez M; Bengió R; Larripa I
Eur J Haematol; 2009 Apr; 82(4):292-300. PubMed ID: 19191867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]